Precision Diagnostics for CNS Metastases

Emerging data highlights the potential of the CNSide® cerebrospinal fluid (CSF) assay platform as a sensitive and precise tool for diagnosing and longitudinally monitoring leptomeningeal disease (LMD), a life-threatening complication of metastatic cancers such as breast and lung cancer.

This growing body of evidence demonstrates how CNSide® is redefining the landscape of cancer diagnostics, particularly in neuro-oncology and precision medicine.

Why CNSide® Research Matters

• Addresses a Diagnostic Gap: Traditional CSF cytology has limited sensitivity, often leading to delayed or missed diagnoses. CNSide® offers 92% sensitivity and 95% specificity, setting a new benchmark for clinical accuracy.
• Supports Longitudinal Monitoring: By quantifying tumor cells and biomarkers in CSF, CNSide® enables clinicians to track disease progression and treatment response over time, helping guide more informed care decisions.
• Backed by Peer-Reviewed Data: The CNSide platform has been featured in several scientific publications, further validating its clinical utility (CNSide Publications).

Clinical Applications for Leptomeningeal Metastases (LM)

• Solid Tumor Relevance: Studies show CNSide® may be especially effective in detecting LM originating from breast cancer, lung cancer, and other solid tumors.
• Personalized Cancer Care: CNSide’s ability to provide sensitive, quantitative insights allows oncologists to tailor treatment strategies with greater precision.
• Ongoing Research: The platform is continuously being evaluated in collaboration with leading cancer institutions, reinforcing its potential to become a standard-of-care diagnostic tool in LM.

External References

• National Cancer Institute – Leptomeningeal Metastases Overview
• Journal of Clinical Oncology – Advances in LM Diagnosis
• Society for Neuro-Oncology (SNO)

The CNSide® CSF assay platform is paving the way for more accurate, sensitive, and actionable cancer diagnostics, particularly in the challenging space of leptomeningeal metastases. Backed by peer-reviewed publications and real-world clinical use, CNSide® continues to demonstrate how precision diagnostics can directly impact patient care.

Explore the full list of CNSide research publications here.

#CNSide #LiquidBiopsy #NeuroOncology #CancerDiagnostics #PrecisionMedicine #CNSMetastases #LeptomeningealMetastases #BrainCancer #LM